
Oric Pharmaceuticals (ORIC) Stock Forecast & Price Target
Oric Pharmaceuticals (ORIC) Analyst Ratings
Bulls say
ORIC Pharmaceuticals Inc. is positioned for a promising future, with its focus on innovative therapies aimed at overcoming resistance mechanisms in cancer, specifically through its lead product candidate, ORIC-944. The company's recent updates on clinical data and positive feedback from key opinion leaders highlight the scientific rationale backing the development of its product candidates, suggesting a favorable outlook as the company navigates a catalyst-rich period over the next 18 months. Furthermore, ORIC has successfully extended its cash runway into 2027, providing a solid financial foundation to support its ongoing research and development initiatives.
Bears say
ORIC Pharmaceuticals is projecting a significant net loss of $2.22 per share for the full year 2025, which raises concerns about the company's financial stability. The potential inability to advance key pipeline candidates ORIC-114 and ORIC-944, coupled with risks associated with negative clinical outcomes and regulatory delays, poses substantial challenges to the company's growth prospects. Additionally, factors such as slower market uptake, lower-than-expected peak sales, and long-term dilution risk further exacerbate the negative outlook for ORIC Pharmaceuticals's stock.
This aggregate rating is based on analysts' research of Oric Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Oric Pharmaceuticals (ORIC) Analyst Forecast & Price Prediction
Start investing in Oric Pharmaceuticals (ORIC)
Order type
Buy in
Order amount
Est. shares
0 shares